

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT

MEDICAL DEVICE REGISTRATION APPLICATION FOR ClouDT-01

This is a voluntary announcement made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”). The board (the “**Board**”) of directors (“**Directors**”) of the Company is pleased to announce that on December 29, 2023, the Group completed the application for registration as a medical device in the People’s Republic of China in respect of ClouDT-01, a self-developed diabetes-related digital therapeutics product.

ClouDT-01 is a cutting-edge digital therapeutics product for the management of diabetes patients with industry-leading efficacy. By leveraging the Group’s advanced digital medical artificial intelligence foundation model, comprehensive diabetes service management database, and extensive diabetes clinical experience, ClouDT-01 provides sensitivity analysis of related indicators for vital diseases, serving both clinical professionals and patients. It facilitates real-time, dynamic, and comprehensive diabetes management, and further benefits diabetes patients clinically.

The Company is committed to developing world-leading and excellence-driven digital healthcare services and products for the improvement of the accessibility and affordability of healthcare services. The Company adheres to the mission of “bringing digital healthcare to every household” and actively responds to national policies and the goals of Healthy China 2030 by promoting the implementation of innovative technologies related to chronic conditions management, with an aim to render high-quality digital healthcare services and products to benefit a wider range of chronic conditions patients.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
ClouDr Group Limited
Kuang Ming
*Chairman, Executive Director and
Chief Executive Officer*

Hong Kong, January 3, 2024

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*